Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Results 101-120 of 514

Ref Title
TA193 Leukaemia (chronic lymphocytic, relapsed) - rituximab: costing template & report
TA192 Lung cancer (non-small-cell, first line) - gefitinib: costing template
TA191 cancer (advanced) - capecitabine: cost statement
TA190 Lung cancer (non-small-cell) - pemetrexed (maintenance): costing template
TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line): costing statement
TA188 Human growth hormone (somatropin) for the treatment of growth failure in children: costing template and report
TA187 Crohn's disease - infliximab (review) and adalimumab (review of TA40): costing template
TA186 Rheumatoid arthritis - certolizumab pegol: costing statement
TA185 Soft tissue sarcoma - trabectedin: costing statement
TA184 Lung cancer (small-cell) - topotecan: costing statement
TA183 Cervical cancer (recurrent) - topotecan: costing statement
TA182 Acute coronary syndrome - prasugrel: costing template
TA181 Lung cancer (non-small cell, first line treatment) - pemetrexed: costing template
TA180 Psoriasis - ustekinumab: costing statement
TA179 Gastrointestinal stromal tumours - sunitinib: costing template
TA178 Renal cell carcinoma: costing statement
TA177 Eczema (chronic) - alitretinoin: costing template
TA176 Colorectal cancer (first line) - cetuximab: costing template
TA174 Leukaemia (chronic lymphocytic, first line) - rituximab: costing report and template
TA173 Hepatitis B - tenofovir disoproxil fumarate: costing statement

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.